Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (3530)	2/15/1999 4:44:00 PM
From: Graham Marshman	Read Replies (1) \| Respond to of 4028

Haven't seen the news on the wire - maybe waiting for the market to open tomorrow. Nice though, nineteen is a nice number and the access rights to info is good. Graham Universities to Begin Studies With ssDNA Expression Vector HOUSTON -- February 15, 1999 -- Cryogenic Solutions, Inc. (OTC BB: CYGS) announced today that it will begin shipping, at cost, kits of the patented ssDNA intracellular expression vector to scientists at university research facilities. The kits are scheduled to be in the laboratories in the first week of March, 1999. CYGS holds the exclusive rights to the ssDNA expression vector under license from InGene, Inc. Researchers at nineteen universities, each trying to antisense a different gene, have requested the kits. All have experienced the common problem of inserting specific intact oligonucleotides into living cells in sufficient quantities to isolate the function of a gene of interest. "The ssDNA expression vector is the most promising technology yet developed to overcome the "delivery" hurdle that stands between genetic research in the labs and an effective antisense gene therapy in living organisms," said CYGS Financial V.P., Lawrence Wunderlich. "The word 'delivery' is somewhat a misnomer. Once our vector is transfected it actually synthesizes single strands of the programmed DNA sequence inside the cell." The ssDNA vector kits will be provided to university investigators at cost for non-commercial use only. The agreement under which the vector material will be transferred to the universities will facilitate CYGS's documentation of the efficacy of the combined vector and anti-sense technologies.